1. Less than 50 years <br/ >2. With severe COVID-19 symptoms requiring immediate hospitalization <br/ >3. Investigator considers the subject unsuitable for ViraCide <br/ >4. History of symptoms of more than 4 days <br/ >5. COVID-19 diagnosed >2 days ago using oropharyngeal/nasal swab RT-PCR for Sars-Co-V2 <br/ >6. History of cardiopulmonary resuscitation <br/ >7. Subjects having history of organ failure or conditions requiring ICU monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation or any other condition that in the PIâ??s opinion makes the subject unfit to participate <br/ >8. Respiratory failure, ARDS or need of mechanical ventilation <br/ >9. History of acute exacerbation of comorbidity like heart failure, diabetic kedoacidosis, myocardial infection, major cardiac rhythm disorder or any other condition that in the PIâ??s opinion makes the subject unfit to participate <br/ >10. History of or current hepatic failure or severely compromised liver function, or renal failure or having chronic kidney disease or acute renal failure <br/ >11. History of or currently receiving treatment for an endocrine disorder like hypothyroidism, hyperthyroidism that is likely to affect the basal heart rate. <br/ >12. History of or currently under treatment for asthma [exception: patients with history of asthma, not on medications/inhalers/nebulizers for at least 6 months before study start), COPD, bronchiectasis, asbestosis and other such chronic lung conditions that can compromise SpO2 and RR. <br/ >13. HIV, HBsAg, HCV positive <br/ >14. Any condition causing immunodeficiency <br/ >15. Systemic connective tissue disease or any autoimmune disease that is likely to affect HS-CRP levels <br/ >16. History of epilepsy/epileptic fit/convulsions in last 6 months or currently on treatment for it <br/ >17. History of or currently having malignancy and being treated for it. (exception: histologically confirmed and cured carcinoma in situ) <br/ >18. Hypersensitivity reaction to Study drug/placebo <br/ >19. Any psychiatric issue for which the subject is currently undergoing treatment <br/ >20. Any history of drug/alcohol dependence within 30 days of screening or current drug/alcohol dependence <br/ >21. Inability to understand the requirements of the Research Protocol and follow the research procedures. <br/ >22. Pregnant or lactating, <br/ >23. Not willing to use adequate contraception during study duration <br/ >24. Participation in any other clinical study less than 3 months before the start of the study. <br/ >

1. Less than 50 years <br/ >2. With severe COVID-19 symptoms requiring immediate hospitalization <br/ >3. Investigator considers the subject unsuitable for ViraCide <br/ >4. History of symptoms of more than 4 days <br/ >5. COVID-19 diagnosed >2 days ago using oropharyngeal/nasal swab RT-PCR for Sars-Co-V2 <br/ >6. History of cardiopulmonary resuscitation <br/ >7. Subjects having history of organ failure or conditions requiring ICU monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation or any other condition that in the PIâ??s opinion makes the subject unfit to participate <br/ >8. Respiratory failure, ARDS or need of mechanical ventilation <br/ >9. History of acute exacerbation of comorbidity like heart failure, diabetic kedoacidosis, myocardial infection, major cardiac rhythm disorder or any other condition that in the PIâ??s opinion makes the subject unfit to participate <br/ >10. History of or current hepatic failure or severely compromised liver function, or renal failure or having chronic kidney disease or acute renal failure <br/ >11. History of or currently receiving treatment for an endocrine disorder like hypothyroidism, hyperthyroidism that is likely to affect the basal heart rate. <br/ >12. History of or currently under treatment for asthma [exception: patients with history of asthma, not on medications/inhalers/nebulizers for at least 6 months before study start), COPD, bronchiectasis, asbestosis and other such chronic lung conditions that can compromise SpO2 and RR. <br/ >13. HIV, HBsAg, HCV positive <br/ >14. Any condition causing immunodeficiency <br/ >15. Systemic connective tissue disease or any autoimmune disease that is likely to affect HS-CRP levels <br/ >16. History of epilepsy/epileptic fit/convulsions in last 6 months or currently on treatment for it <br/ >17. History of or currently having malignancy and being treated for it. (exception: histologically confirmed and cured carcinoma in situ) <br/ >18. Hypersensitivity reaction to Study drug/placebo <br/ >19. Any psychiatric issue for which the subject is currently undergoing treatment <br/ >20. Any history of drug/alcohol dependence within 30 days of screening or current drug/alcohol dependence <br/ >21. Inability to understand the requirements of the Research Protocol and follow the research procedures. <br/ >22. Pregnant or lactating, <br/ >23. Not willing to use adequate contraception during study duration <br/ >24. Participation in any other clinical study less than 3 months before the start of the study. <br/ >

N/A

N/A

1. Less than 50 years <br/ >2. With severe COVID-19 symptoms requiring immediate hospitalization <br/ >3. Investigator considers the subject unsuitable for ViraCide <br/ >4. History of symptoms of more than 4 days <br/ >5. COVID-19 diagnosed >2 days ago using oropharyngeal/nasal swab RT-PCR for Sars-Co-V2 <br/ >6. History of cardiopulmonary resuscitation <br/ >7. Subjects having history of organ failure or conditions requiring ICU monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation or any other condition that in the PIâ??s opinion makes the subject unfit to participate <br/ >8. Respiratory failure, ARDS or need of mechanical ventilation <br/ >9. History of acute exacerbation of comorbidity like heart failure, diabetic kedoacidosis, myocardial infection, major cardiac rhythm disorder or any other condition that in the PIâ??s opinion makes the subject unfit to participate <br/ >10. History of or current hepatic failure or severely compromised liver function, or renal failure or having chronic kidney disease or acute renal failure <br/ >11. History of or currently receiving treatment for an endocrine disorder like hypothyroidism, hyperthyroidism that is likely to affect the basal heart rate. <br/ >12. History of or currently under treatment for asthma [exception: patients with history of asthma, not on medications/inhalers/nebulizers for at least 6 months before study start), COPD, bronchiectasis, asbestosis and other such chronic lung conditions that can compromise SpO2 and RR. <br/ >13. HIV, HBsAg, HCV positive <br/ >14. Any condition causing immunodeficiency <br/ >15. Systemic connective tissue disease or any autoimmune disease that is likely to affect HS-CRP levels <br/ >16. History of epilepsy/epileptic fit/convulsions in last 6 months or currently on treatment for it <br/ >17. History of or currently having malignancy and being treated for it. (exception: histologically confirmed and cured carcinoma in situ) <br/ >18. Hypersensitivity reaction to Study drug/placebo <br/ >19. Any psychiatric issue for which the subject is currently undergoing treatment <br/ >20. Any history of drug/alcohol dependence within 30 days of screening or current drug/alcohol dependence <br/ >21. Inability to understand the requirements of the Research Protocol and follow the research procedures. <br/ >22. Pregnant or lactating, <br/ >23. Not willing to use adequate contraception during study duration <br/ >24. Participation in any other clinical study less than 3 months before the start of the study. <br/ >

1. Less than 50 years <br/ >2. With severe COVID-19 symptoms requiring immediate hospitalization <br/ >3. Investigator considers the subject unsuitable for ViraCide <br/ >4. History of symptoms of more than 4 days <br/ >5. COVID-19 diagnosed >2 days ago using oropharyngeal/nasal swab RT-PCR for Sars-Co-V2 <br/ >6. History of cardiopulmonary resuscitation <br/ >7. Subjects having history of organ failure or conditions requiring ICU monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation or any other condition that in the PIâ??s opinion makes the subject unfit to participate <br/ >8. Respiratory failure, ARDS or need of mechanical ventilation <br/ >9. History of acute exacerbation of comorbidity like heart failure, diabetic kedoacidosis, myocardial infection, major cardiac rhythm disorder or any other condition that in the PIâ??s opinion makes the subject unfit to participate <br/ >10. History of or current hepatic failure or severely compromised liver function, or renal failure or having chronic kidney disease or acute renal failure <br/ >11. History of or currently receiving treatment for an endocrine disorder like hypothyroidism, hyperthyroidism that is likely to affect the basal heart rate. <br/ >12. History of or currently under treatment for asthma [exception: patients with history of asthma, not on medications/inhalers/nebulizers for at least 6 months before study start), COPD, bronchiectasis, asbestosis and other such chronic lung conditions that can compromise SpO2 and RR. <br/ >13. HIV, HBsAg, HCV positive <br/ >14. Any condition causing immunodeficiency <br/ >15. Systemic connective tissue disease or any autoimmune disease that is likely to affect HS-CRP levels <br/ >16. History of epilepsy/epileptic fit/convulsions in last 6 months or currently on treatment for it <br/ >17. History of or currently having malignancy and being treated for it. (exception: histologically confirmed and cured carcinoma in situ) <br/ >18. Hypersensitivity reaction to Study drug/placebo <br/ >19. Any psychiatric issue for which the subject is currently undergoing treatment <br/ >20. Any history of drug/alcohol dependence within 30 days of screening or current drug/alcohol dependence <br/ >21. Inability to understand the requirements of the Research Protocol and follow the research procedures. <br/ >22. Pregnant or lactating, <br/ >23. Not willing to use adequate contraception during study duration <br/ >24. Participation in any other clinical study less than 3 months before the start of the study. <br/ >